Pfizer Inc.’s Covid-19 vaccine provided a strong shield against hospitalization and more severe disease in cases caused by the contagious delta variant in Israel in recent weeks, even though it was just 39% effective in preventing infections, according to the country’s health ministry.
The vaccine, developed with BioNTech SE, provided 88% protection against hospitalization and 91% against severe illness for an unspecified number of people studied between June 20 and July 17, according to a report Thursday from the health ministry.
The data could be skewed because of different ways of testing vaccinated groups of people versus those who hadn’t been inoculated, according to the report.
“The heavily skewed exposure patterns in the recent outbreak in Israel, which are limited to specific population sectors and localities,” means the analysis may not be able to take all factors into account, said Ran Balicer, chairman of Israel’s national expert advisory team on Covid-19 response. “We are trying to complement this research approach with additional ones, taking additional personal characteristics into account. But this takes time and larger case numbers.”
Still, the data are likely to fuel debate over whether booster shots should be given to people who’ve already been vaccinated -- something Pfizer has said it plans to request in the U.S. Israeli authorities said earlier this month they’ll only give a third round of shots to people with weakened immune systems.
The data out of Israel, which had earlier access to vaccines than most anywhere else in the world, contrast with a study out of the U.K. That paper, published this week in the New England Journal of Medicine, found that two doses of the Pfizer-BioNTech vaccine offer 88% protection against symptomatic disease caused by the delta variant and 94% against the alpha variant that was first discovered in Britain. Public Health England also previously found that the Pfizer and BioNTech shot was 96% effective against hospitalization.
Pfizer and BioNTech are confident in the protection and safety of the two-dose vaccine, Pfizer said in a statement on Friday. BioNTech is conducting a review of study data on the vaccine, a spokeswoman said.
Analysis of the companies’ more than 43,000-person clinical trial shows that effectiveness against symptomatic infection dips over time, from 95% in the first two months to the low- to mid-80% range four to six months after the second dose, Pfizer said.
The delta variant first emerged in India and is spreading around the globe, sometimes infecting those already fully vaccinated against Covid. The mutation has promted some countries to step up inoculation campaigns and rethink plans to loosen curbs on businesses, activity and travel.
Israel has had one of the world’s most effective immunization drives, with 57% of the population fully vaccinated, but has seen a recent surge in infections due to delta. Critical cases have also climbed, but remain a fraction of the peak earlier this year.
Prime Minister Naftali Bennett has urged vaccine holdouts -- who number some 1.1 million people -- to get inoculated, calling it the most effective way to defeat the delta strain. The government has also reinstated some restrictions for indoor events and plans to ban flights to several countries with rising infection rates, including the U.K. and Cyprus.